During the past decade, Onkozentrum Dresden conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 3 clinical trials were completed, i.e. on average, 20% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 3 clinical trials were completed. i.e. 27.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Onkozentrum Dresden" #1 sponsor was "Hoffmann-La Roche" with 4 trials, followed by "Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest" with 3 trials sponsored, "Egetis Therapeutics" with 2 trials sponsored, "AGO Research GmbH" with 1 trials sponsored and "Daiichi Sankyo, Inc." with 1 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Onkozentrum Dresden" #1 collaborator was "Roche Pharma AG" with 2 trials as a collaborator, "Solasia Pharma K.K." with 2 trials as a collaborator, "ARCAGY/ GINECO GROUP" with 1 trials as a collaborator, "Alliance Foundation Trials (AFT)" with 1 trials as a collaborator and "Arbeitsgemeinschaft Gynaekologische Onkologie Austria" with 1 trials as a collaborator. Other collaborators include 10 different institutions and companies that were collaborators in the rest 20 trials.

According to Clinical.Site data, the most researched conditions in "Onkozentrum Dresden" are "Colorectal Cancer" (3 trials), "Chemotherapy-induced Peripheral Neuropathy" (2 trials), "Cholangiocarcinoma" (2 trials), "Gallbladder Cancer" (2 trials) and "Hepatocellular Cancer" (2 trials). Many other conditions were trialed in "Onkozentrum Dresden" in a lesser frequency.

Most popular intervention types in "Onkozentrum Dresden" are "Drug" (12 trials), "Other" (4 trials), "Biological" (1 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Atezolizumab" (2 trials), "Calmangafodipir (5 µmol/kg)" (2 trials), "Paclitaxel" (2 trials) and "Trastuzumab Emtansine" (2 trials). Other intervention names were less common.

The vast majority of trials in "Onkozentrum Dresden" are 15 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Onkozentrum Dresden". undefined are not yet recruiting, 9 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Onkozentrum Dresden, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Onkozentrum Dresden, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".